126 related articles for article (PubMed ID: 31262426)
1. Highly effective sirolimus therapy for abdominal lymphangioleiomyoma.
Lecuelle D; Basille D; Renard C; Saint F; Jounieaux V
Respir Med Res; 2019 May; 75():32-34. PubMed ID: 31262426
[No Abstract] [Full Text] [Related]
2. Resolution of Thoracic and Abdominal Lymphangioleiomyomas in a Patient With Lymphangioleiomyomatosis Treated With Sirolimus.
Cabeza Osorio L; Ruiz Cobos MÁ; Casanova Espinosa Á
Arch Bronconeumol; 2016 Jun; 52(6):329-30. PubMed ID: 25912780
[No Abstract] [Full Text] [Related]
3. Changes in lung function and chylous effusions in patients with lymphangioleiomyomatosis treated with sirolimus.
Taveira-DaSilva AM; Hathaway O; Stylianou M; Moss J
Ann Intern Med; 2011 Jun; 154(12):797-805, W-292-3. PubMed ID: 21690594
[TBL] [Abstract][Full Text] [Related]
4. Rapid Shrinkage of Retroperitoneal Lymphangioleiomyoma after Sirolimus Initiation.
Hirose M; Ishimaru Y; Sakata S; Sakagami T
Intern Med; 2022 Jul; 61(13):2081-2082. PubMed ID: 34840234
[No Abstract] [Full Text] [Related]
5. Sirolimus Therapy for Patients With Lymphangioleiomyomatosis Leads to Loss of Chylous Ascites and Circulating LAM Cells.
Harari S; Elia D; Torre O; Bulgheroni E; Provasi E; Moss J
Chest; 2016 Aug; 150(2):e29-32. PubMed ID: 27502989
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of low-dose sirolimus for treatment of lymphangioleiomyomatosis.
Ando K; Kurihara M; Kataoka H; Ueyama M; Togo S; Sato T; Doi T; Iwakami S; Takahashi K; Seyama K; Mikami M
Respir Investig; 2013 Sep; 51(3):175-83. PubMed ID: 23978644
[TBL] [Abstract][Full Text] [Related]
7. What׳s the role of sirolimus on the treatment of lymphangioleiomyomatosis (LAM)?: Merely tuning up of LAM-associated dysfunctional lymphatic vessels rather than cytoreduction?
Suina K; Hayashi T; Mitani K; Suzuki K; Takahashi K; Seyama K
Respir Investig; 2014 Jul; 52(4):274-6. PubMed ID: 24998376
[No Abstract] [Full Text] [Related]
8. Sustained effects of sirolimus on lung function and cystic lung lesions in lymphangioleiomyomatosis.
Yao J; Taveira-DaSilva AM; Jones AM; Julien-Williams P; Stylianou M; Moss J
Am J Respir Crit Care Med; 2014 Dec; 190(11):1273-82. PubMed ID: 25329516
[TBL] [Abstract][Full Text] [Related]
9. SUCCESSFUL TREATMENT OF PULMONARY AND LYMPHATIC MANIFESTATIONS OF LYMPHANGIOLEIOMYOMATOSIS WITH SIROLIMUS.
Hecimovic A; Jakopovic M; Pavlisa G; Jankovic M; Vukic-Dugac A; Redzepi G; Brcic L; Samarzija M; Gupta N
Lymphology; 2015 Jun; 48(2):97-102. PubMed ID: 26714374
[TBL] [Abstract][Full Text] [Related]
10. Sirolimus for lymphangioleiomyomatosis lesions.
Egan JJ; Remund KF; Corris P
N Engl J Med; 2008 May; 358(18):1963-4; author reply 1964. PubMed ID: 18450609
[No Abstract] [Full Text] [Related]
11. Variability in the prevalence of acute bronchoresponsiveness in different populations of patients with lymphangioleiomyomatosis.
Burger CD
Chest; 2008 Jul; 134(1):217; author reply 218. PubMed ID: 18628234
[No Abstract] [Full Text] [Related]
12. Durability of Sirolimus for Lymphangioleiomyomatosis.
Martirossian A; Shah S; Carrete L; Valle J; Valentine V
Am J Med Sci; 2017 Dec; 354(6):603-607. PubMed ID: 29208258
[TBL] [Abstract][Full Text] [Related]
13. Effects of sirolimus in lymphangioleiomyomatosis patients on lung cysts and pulmonary function: long-term follow-up observational study.
Kim C; Do KH; Cha J; Song JW; Lee SM; Lee KY
Eur Radiol; 2020 Feb; 30(2):735-743. PubMed ID: 31471750
[TBL] [Abstract][Full Text] [Related]
14. Response of lymphangioleiomyomatosis to a mammalian target of rapamycin inhibitor (temsirolimus) -based treatment.
Piha-Paul SA; Hong DS; Kurzrock R
J Clin Oncol; 2011 Apr; 29(12):e333-5. PubMed ID: 21263090
[No Abstract] [Full Text] [Related]
15. A Novel Quantitative Computed Tomographic Analysis Suggests How Sirolimus Stabilizes Progressive Air Trapping in Lymphangioleiomyomatosis.
Argula RG; Kokosi M; Lo P; Kim HJ; Ravenel JG; Meyer C; Goldin J; Lee HS; Strange C; McCormack FX;
Ann Am Thorac Soc; 2016 Mar; 13(3):342-9. PubMed ID: 26799509
[TBL] [Abstract][Full Text] [Related]
16. Lymphangioleiomyomatosis. Diagnostic imaging approach to a rare disease in women.
Hede J; Jurik AG
Rofo; 1991 Dec; 155(6):582-4. PubMed ID: 1764603
[No Abstract] [Full Text] [Related]
17. Retroperitoneal lymphangioleiomyoma with lymph node involvement: A pathologic-radiologic correlation of a rare form of myomelanocytic tumor.
Abdelkader A; Lam CA; Shahir KS; Christians K; Suster SM
Ann Diagn Pathol; 2017 Apr; 27():69-73. PubMed ID: 28325364
[TBL] [Abstract][Full Text] [Related]
18. Lymphangioleiomyomatosis.
Sclafani A; VanderLaan P
N Engl J Med; 2018 Jun; 378(23):2224. PubMed ID: 29874537
[No Abstract] [Full Text] [Related]
19. Regression of pulmonary lymphangioleiomyomatosis (PLAM)-associated retroperitoneal angiomyolipoma post-lung transplantation with rapamycin treatment.
Morton JM; McLean C; Booth SS; Snell GI; Whitford HM
J Heart Lung Transplant; 2008 Apr; 27(4):462-5. PubMed ID: 18374885
[TBL] [Abstract][Full Text] [Related]
20. Use of sirolimus in the treatment of lymphangioleiomyomatosis: favorable responses in patients with different extrapulmonary manifestations.
Freitas CS; Baldi BG; Araújo MS; Heiden GI; Kairalla RA; Carvalho CR
J Bras Pneumol; 2015; 41(3):275-80. PubMed ID: 26176526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
